Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
Quentin KlopfensteinValentin DerangèreLaurent ArnouldMarion ThibaudinEmeric LimagneFrançois GhiringhelliCaroline TruntzerSylvain LadoirePublished in: Journal for immunotherapy of cancer (2021)
Our findings make it possible to refine the survival stratification of early patients with breast cancer by incorporating TIC in addition to PAM50 and clinical tumor burden in a prognostic model validated in training and validation cohorts.